沉默调节蛋白1在非酒精性脂肪性肝病发生发展中的作用

杨帅; 何松青

doi:10.3969/j.issn.1001-5256.2018.03.047

沉默调节蛋白1在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2018.03.047

杨帅,
何松青

1. 桂林医学院
2. 桂林医学院附属医院

基金项目:

国家自然科学基金重点项目(81430014);国家自然科学基金面上项目(31370917)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2256
- HTML全文浏览量: 52
- PDF下载量: 416
- 被引次数: 0
出版历程
- 出版日期: 2018-03-20

Role of silent information regulator 1 in development and progression of nonalcoholic fatty liver disease

Guilin Medical University

Research funding:

摘要

摘要: 沉默调节蛋白1（SIRT1）为Sirtuin家族的一员,是依赖于烟酰腺嘌呤二核苷酸（NAD+）的去乙酰化酶,其主要作用是参与能量代谢﹑细胞生存、衰老及凋亡。而非酒精性脂肪性肝病（NAFLD）是一种与胰岛素抵抗、氧化应激及脂质过氧化等密切相关的慢性肝脏疾病。从SIRT1与NAFLD者的能量代谢关系﹑SIRT1与氧化应激、脂质过氧化、内质网应激等方面进行了阐述,认为SIRT1与NAFLD的发生发展密切相关。
- 非酒精性脂肪性肝病 /
- 沉默调节蛋白-1 /
- 胰岛素抵抗 /
- 内质网应激 /
- 综述
Abstract: Silent information regulator 1 ( SIRT1) , a member of the Sirtuin family, is a deacetylase depending on nicotinamide adenine dinucleotide and is mainly involved in energy metabolism, cell survival, aging, and apoptosis. Nonalcoholic fatty liver disease ( NAFLD) is a chronic liver disease closely related to insulin resistance, oxidative stress, and lipid peroxidation. This article elaborates on the association of SIRT1 with energy metabolism, oxidative stress, lipid peroxidation, and endoplasmic reticulum stress and points out that SIRT1 is closely associated with the development and progression of NAFLD.
- non-alcoholic fatty liver disease /
- silent information regulator transcription 1 /
- insulin resistance /
- endoplasmic reticulum stress /
- review

HTML全文

参考文献(34)

[1]CHANG BX.An excerpt of EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease (2016) [J].J Clin Hepatol, 2016, 32 (8) :1450-1454. (in Chinese) 常彬霞.《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南:非酒精性脂肪性肝病》摘译[J].临床肝胆病杂志, 2016, 32 (8) :1450-1454.

[2]ANGULO P, KLEINER DE, DAMLARSEN S, et al.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J].Gastroenterology, 2015, 149 (2) :389-397.

[3]CARR RM, ORANU A, KHUNGAR V.Nonalcoholic fatty liver disease:pathophysiology and management[J].Gastroenterol Clin, 2016, 45 (4) :639-652.

[4]HAAS JT, FRANCQUE S, STAELS B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Physiol, 2016, 78 (1) :181.

[5]LIU YF, XIE W.Advances in the treatment of non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (1) :26-28. (in Chinese) 刘玉凤, 谢雯.非酒精性脂肪性肝病治疗进展[J/CD].中国肝脏病杂志:电子版, 2016, 8 (1) :26-28.

[6]XU CC, SHANG WB.Research progress in SIRT1 and metabolic diseases[J].J Hainan Med, 2016, 27 (5) :785-787. (in Chinese) 徐传翀, 尚文斌.SIRT1与代谢相关疾病的研究进展[J].海南医学, 2016, 27 (5) :785-787.

[7]CANTO C, AUWERX J.TARGETING.Sirtuin 1 to improve metabolism:all you need is NAD (+) ?[J].Pharmacol Rev, 2012, 64 (1) :166.

[8]LI X.SIRT1 and energy metabolism[J].Acta Biochim Biophys sin (shanghai) , 2013, 45 (1) :51-60.

[9]CAO Y, JIANG X, MA H, et al.SIRT1 and insulin resistance[J].J Diabetes Complications, 2016, 30 (1) :178-183.

[10]LIU X, EHMED E, LI B, et al.Breast cancer metastasis suppressor 1 modulates SIRT1-dependent p53 deacetylation through interacting with DBC1[J].Am J Cancer Res, 2016, 6 (6) :1441-1449.

[11]MENDELSOHN AR, LARRICK J.The NAD+/PARP1/SIRT1 axis in aging[J].Rejuvenation Res, 2017, 20 (3) :244-247.

[12]HOU Y, SU B, CHEN P, et al.Association of SIRT1 gene polymorphism and its expression for the risk of alcoholic fatty liver disease in the Han population[J].Hepatol Intern, 2017.[Epub ahead of print]

[13]LI JX, DOU XB, LI ST, et al.Nicotinamide ameliorates palmitate-induced ER stress in hepatocytes via c AMP/PKA/CREB pathway-depen dent Sirt1 upregulation[J].Biochimi Biophys Acta, 2015, 1853 (11) :2929.

[14]LI Y, HONG ZF.Hypothesis of"Two Hits"in NAFLD[J].Med Recapitul, 2013, 19 (4) :594-596. (in Chinese) 李颖, 洪振丰.“二次打击”假说与非酒精性脂肪肝[J].医学综述, 2013, 19 (4) :594-596.

[15]DARA L, JI C, KAPLOWITZ N.The contribution of endoplasmic reticulum stress to liver diseases[J].Hepatology, 2011, 53 (5) :1752-1763.

[16]KITADE H, CHEN G, NI Y, et al.Nonalcoholic fatty liver disease and insulin resistance:new insights and potential new treatments[J].Nutrients, 2017, 9 (4) :387.

[17]LI Y, XU S, GILES A, et al.Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver[J].FASEB J, 2011, 25 (5) :1664-1679.

[18]HU X, CHI L, ZHANG W, et al.Down-regulation of the miR-543 alleviates insulin resistance through targeting the SIRT1[J].Biochem Biophys Res Commun, 2015, 468 (4) :781.

[19]LIU J, ZHOU B, YAN M, et al.CLOCK and BMAL1 regulate muscle insulin sensitivity via SIRT1 in male mice[J].Endocrinol, 2016, 157 (6) :2259.

[20]FISHER FM, CHUI PC, NASSER IA, et al.Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets[J].Gastroenterol, 2014, 147 (5) :1073.

[21]LI Y, WONG K, WALSH K, et al.Retinoic acid receptorβstimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice[J].J Biol Chem, 2013, 288 (15) :10490-10504.

[22]YUAN RS, LI H, SUN JH, et al.Lipid-lowering effect and antioxidant activity of polysaccharide from Schisandra Chinensis rats with non-alcoholic fatty liver disease induced by high-fat diet[J].J Jilin Univ:Med Edit, 2017, 43 (6) :1103-1108. (in Chinese) 苑荣爽, 李贺, 孙靖辉, 等.北五味子多糖对高脂诱导非酒精性脂肪性肝病大鼠的降血脂作用及其抗氧化活性[J].吉林大学学报:医学版, 2017, 43 (6) :1103-1108.

[23]SPAHIS S, DELVIN E, BORYS JM, et al.Oxidatibe stress as a critical factor in nonalcoholic fatty liver disease pathogenesis[J].Antioxid Redox Signal, 2017, 26 (10) :519-541.

[24]CHEN G, NI Y, NAGATA N, et al.Micronutrient antioxidants and nonalcoholic fatty liver disease[J].Int J Mol Sci, 2016, 17 (9) :1379.

[25]BU X, WU, LU X, et al.Role of SIRT1/PGC-1 in mitochondrial oxidative stress in autistic spectrum disorder[J].Neuropsychiatr Dis Treat, 2017, 23 (13) :1633-1645.

[26]ZHANG L, TU R, WANG Y, et al.Early-life exposure to lead induces cognitive impairment in elder mice targeting SIRT1 phosphorylation and oxidative alterations[J].Front Physiol, 2017, 29 (6) :38-44.

[27]CHAN SH, HUANG CH, SHIH JY, et al.SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease[J].Redox Biol, 2017, 13 (10) :301-309.

[28]SINGH P, HANSON PS, MORRIS CM.SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease[J].BMC Neurosci, 2017, 18 (1) :46.

[29]ZHANG W, CHEN Z, ZHANG Y, et al.Sirt1 Inhibits oxidative stress in vascular endothelial cells[J].Oxid Med Cell Longev, 2017, 2017:7543973.

[30]JANG MK, HAN YR, NAM JS, et al.Protective effects of alismaorientale extract against hepatic steatosis via inhibition of endoplasmic reticulum stress[J].Int J Mol Sci, 2015, 16 (11) :26151-26165.

[31]SOEDA J, CORDERO P, LI J, et al.Hepatic rhythmicity of endoplasmic reticulum stress is disrupted in perinatal and adult mice models of high-fat diet-induced obesity[J].Int J Food Sci Nutr, 2016, 68 (4) :455-466.

[32]LIU H, LI CJ, WANG HN, et al.Mechanism of SIRT1 promoting the proliferation of hepatocytes[J].J Pract Med, 2013, 29 (16) :2634-2637. (in Chinese) 刘灏, 李川江, 王汉宁, 等.沉默信息调节因子1促进肝细胞增殖的机制[J].实用医学杂志, 2013, 29 (16) :2634-2637.

[33]DENG XQ, CHEN LL, LI NX.The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats[J].Liver Int, 2007, 27 (5) :708-715.

[34] ZOU FY, WEN XR, WANG YL.Correlation research of sirtuin factor 1 (Sirt1) and non-alcoholic fatty liver[J].Chin J Tradit Med Sci Technol, 2014, 21 (22) :58-59. (in Chinese) 邹伏英, 温孝如, 王友莲.沉默信息调节因子1 (Sirt1) 和非酒精性脂肪肝的相关性研究[J].中国中医药科技, 2014, 21 (22) :58-59.

施引文献

资源附件(0)

访问统计